middle.news
Opthea Returns to ASX with OPT-302 Targeting Rare Lung Disease LAM
8:48am on Wednesday 3rd of June, 2026 AEST
•
Healthcare
Read Story
Opthea Returns to ASX with OPT-302 Targeting Rare Lung Disease LAM
8:48am on Wednesday 3rd of June, 2026 AEST
Key Points
ASX trading reinstated on 3 June 2026
OPT-302 development targets rare lung disease LAM
Three-stage 18-month clinical program underway
A$13.1 million budgeted from A$31.2 million cash reserves
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Opthea (ASX:OPT)
OPEN ARTICLE